Scarica l'app Stockscreener
2.04
0.99%
0.02
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$2.02
Aprire:
$1.98
Volume 24 ore:
4,336
Relative Volume:
0.18
Capitalizzazione di mercato:
$23.50M
Reddito:
$3.02M
Utile/perdita netta:
$-653.00K
Rapporto P/E:
-41.38
EPS:
-0.0493
Flusso di cassa netto:
$2.42M
1 W Prestazione:
+1.49%
1M Prestazione:
-3.32%
6M Prestazione:
+4.08%
1 anno Prestazione:
+39.73%
Intervallo 1D:
$1.98
$2.0398
Intervallo di 1 settimana:
$1.93
$2.10
Portata 52W:
$0.9811
$2.95
Therapeuticsmd Inc Stock (TXMD) Company Profile
Nome
Therapeuticsmd Inc
Settore
Telefono
561-961-1900
Indirizzo
951 YAMATO ROAD, SUITE 220, BOCA RATON, FL
Compare TXMD vs TAK, TEVA, HLN, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TXMD
Therapeuticsmd Inc
|
2.03 | 23.38M | 3.02M | -653.00K | 2.42M | -0.0493 |
TAK
Takeda Pharmaceutical Co Adr
|
16.64 | 52.58B | 29.85B | 776.90M | 4.35B | 0.2408 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.34 | 42.21B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
8.955 | 39.99B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
75.36 | 31.17B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
572.65 | 24.60B | 3.17B | 1.29B | 1.01B | 27.09 |
Therapeuticsmd Inc Stock (TXMD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-08-07 | Downgrade | Jefferies | Hold → Underperform |
| 2020-05-19 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-12-02 | Iniziato | Guggenheim | Buy |
| 2019-10-17 | Iniziato | H.C. Wainwright | Buy |
| 2019-04-30 | Ripresa | Noble Capital Markets | Outperform |
| 2018-06-15 | Iniziato | JP Morgan | Overweight |
| 2017-09-08 | Iniziato | Morgan Stanley | Equal-Weight |
| 2017-07-11 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2017-05-09 | Downgrade | Oppenheimer | Outperform → Perform |
| 2016-11-22 | Ripresa | Jefferies | Buy |
| 2016-11-22 | Iniziato | Oppenheimer | Outperform |
| 2016-11-07 | Ripresa | Guggenheim | Buy |
| 2016-04-04 | Iniziato | Goldman | Buy |
| 2015-12-08 | Reiterato | Jefferies | Buy |
| 2015-12-08 | Reiterato | Stifel | Buy |
| 2015-09-21 | Reiterato | Jefferies | Buy |
| 2015-06-09 | Iniziato | Guggenheim | Buy |
| 2014-07-08 | Iniziato | FBR Capital | Outperform |
| 2014-04-17 | Reiterato | Noble Financial | Buy |
| 2014-01-28 | Reiterato | Noble Financial | Buy |
Mostra tutto
Therapeuticsmd Inc Borsa (TXMD) Ultime notizie
TherapeuticsMD Inc. stock outperforms competitors on strong trading day - MarketWatch
TherapeuticsMD Announces First Quarter 2026 Financial Results - BioSpace
TXMD Reports Strong Q1 Revenue Growth and Explores Strategic Alt - GuruFocus
Is TherapeuticsMD (TXMD) 13.4% Overvalued After Q1 2026 Earnings - GuruFocus
[10-Q] TherapeuticsMD, Inc. Quarterly Earnings Report - Stock Titan
TherapeuticsMD Reports Quarterly Profit, Evaluates Strategic Alternatives - TipRanks
TherapeuticsMD: Q1 Earnings Snapshot - marketscreener.com
TherapeuticsMD swings to Q1 net income as license revenue rises - TradingView
TherapeuticsMD (TXMD) details Q1 2026 results and strategic review - Stock Titan
TherapeuticsMD Inc. stock underperforms Monday when compared to competitors - MarketWatch
TherapeuticsMD Inc. stock underperforms Friday when compared to competitors - MarketWatch
TherapeuticsMD Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
TXMD Stock Price, Quote & Chart | THERAPEUTICSMD INC (NASDAQ:TXMD) - ChartMill
TherapeuticsMD Inc. stock underperforms Thursday when compared to competitors - MarketWatch
TXMD Should I Buy - Intellectia AI
TXMD (TherapeuticsMD Inc.) posts far wider Q3 2023 loss than expected, with shares dipping 0.48% in today’s trading.Stock Community Signals - Cổng thông tin điện tử tỉnh Tây Ninh
TXMD (TherapeuticsMD Inc.) Q3 2023 EPS misses consensus estimates by wide margin as shares dip 0.48 percent in today's trading.Trending Stock Ideas - Cổng thông tin điện tử tỉnh Tây Ninh
Form 10-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]: [Amend] - ADVFN
Total debt per share of TherapeuticsMD, Inc. – MUN:29TA - TradingView — Track All Markets
TherapeuticsMD Inc. stock rises Wednesday, still underperforms market - MarketWatch
TherapeuticsMD Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
[SCHEDULE 13G] TherapeuticsMD, Inc. Passive Investment Disclosure (>5%) - Stock Titan
Profit Recap: Is TherapeuticsMD Inc stock a buy or sell2026 Review & Real-Time Volume Trigger Notifications - baoquankhu1.vn
TherapeuticsMD Inc. (TXMD) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
TherapeuticsMD Inc. R (29TA.F) stock price, news, quote and history - Yahoo Finance UK
TherapeuticsMD Explains Brief Delay In Annual Filing - The Globe and Mail
TherapeuticsMD 2025 Annual Report: Business Overview, Risk Factors, and Intellectual Property Challenges - Minichart
[10-K/A] TherapeuticsMD, Inc. Amends Annual Report - Stock Titan
TherapeuticsMD Inc. stock rises Tuesday, still underperforms market - MarketWatch
TherapeuticsMD, Inc. (TXMD) stock price, news, quote and history - Yahoo Finance UK
TherapeuticsMD Announces Full Year 2025 Financial Results - BioSpace
TherapeuticsMD (NASDAQ: TXMD) files 2025 Form 10-K after printer error - Stock Titan
TherapeuticsMD Narrows 2025 Loss, Advances Royalty Strategy - TipRanks
TXMD Reports $7.5 Million in Cash Holdings as of Year-End 2025 - GuruFocus
TXMD: Net loss narrowed and license revenue surged as strategic alternatives are explored - TradingView
TXMD: 2025 saw improved results from royalty revenue, but litigation and liquidity risks threaten viability - TradingView — Track All Markets
TherapeuticsMD (NASDAQ: TXMD) reports 2025 results, weighs strategic options - Stock Titan
[10-K] TherapeuticsMD, Inc. Files Annual Report - Stock Titan
TXMD Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
TherapeuticsMD, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Therapeuticsmd Inc Azioni (TXMD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.09%
3.08%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):